Effect of bone marrow mesenchymal stem cells on the gene therapy of Parkinson disease
- VernacularTitle:骨髓基质干细胞在帕金森病基因治疗中的效应
- Author:
Jingcheng LI
;
Zhengze WANG
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2007;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: We investigated the development of the studying of bone marrow mesenchymal stem cells (MSCs) and elucidated the feasibility of gene therapy for Parkinson's disease. DATA SOURCES: Using the key terms "mesenchymal stem cells, Parkinson disease, gene transfer", we searched the MEDLINE database for the articles published in English from January 2000 to December 2005. Meanwhile, Wanfang database was retrieved for the relevant articles published during the same period, with the keywords of "Parkinson's disease, gene therapy, gene transfer, mesenchymal stem cells" in Chinese. STUDY SELECTION: All articles were selected firstly and those were relevant to gene therapy of Parkinson disease, differentiation of MSCs into nerve stem cells, or the therapy of MSCs transplantation for Parkinson disease. DATA EXTRACTION: A total of 158 articles including 32 Chinese and 126 English were collected, finally 30 articles of them were included. DATA SYNTHESIS: Parkinson disease is a very normal disorder of central nerve systematic degeneration, which pathological change is the damage of dopamine neuron in substantia nigra. Nowadays the systematic study of Parkinson disease indicates that transplantation of MSCs has a potential prospective application. Due to the autospecific superiority, MSCs become an engineering cell of Parkinson disease therapy. In recent years there are a lot of researches on genetic modification about MSCs that involved in gene therapy as an ideal target cell. MSCs can improve the dopamine synthesis and decrease the death of dopaminergic neuron. Target gene encoding enzymes in the route of dopamine synthesis, such as Tyrosine Hydroxylase, Aromatic L-Aminoacid Decarboxylase and neural protective molecule including neurotrophic factor and anti-apoptosis protein, is in the state of animal experiments, which provide great space for treating neurodegenerative disease-Parkinson disease. CONCLUSION: As MSCs are the plentiful sources of engineering cells, which have an extensive prospective application, it has potential clinical value in treating Parkinson disease, especially in gene therapy of Parkinson's disease.
